SEC Comment Letter for Voyager Therapeutics, (VYGR) — Nov 9, 2022
Voyager Therapeutics, Inc.
Date: Nov. 9, 2022 · CIK: 0001640266 · Accession: 0000000000-22-012219
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268240
Letter
United States securities and exchange commission logo November 9, 2022 Alfred Sandrock President and Chief Executive Officer Voyager Therapeutics, Inc. 64 Sidney Street Cambridge, Massachusetts 02139 Re:Voyager Therapeutics, Inc. Registration Statement on Form S-3 Filed November 8, 2022 File No. 333-268240 Dear Alfred Sandrock: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brian A. Johnson, Esq.
Show Raw Text
United States securities and exchange commission logo
November 9, 2022
Alfred Sandrock
President and Chief Executive Officer
Voyager Therapeutics, Inc.
64 Sidney Street
Cambridge, Massachusetts 02139
Re:Voyager Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 8, 2022
File No. 333-268240
Dear Alfred Sandrock:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brian A. Johnson, Esq.